Skip to Content

The originating document has been archived. We cannot confirm the completeness, accuracy and currency of the content.

Elvitegravir Dosage

Applies to the following strength(s): 85 mg ; 150 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for HIV Infection

With once-daily atazanavir/ritonavir or twice-daily lopinavir-ritonavir: 85 mg orally once a day with food
With twice-daily darunavir/ritonavir, fosamprenavir/ritonavir, or tipranavir/ritonavir: 150 mg orally once a day with food

-The manufacturer product information should be consulted for the recommended dosing regimen for atazanavir/ritonavir, lopinavir-ritonavir, darunavir/ritonavir, fosamprenavir/ritonavir, or tipranavir/ritonavir; this drug should not be used with other dose regimens or HIV-1 protease inhibitors.
-This drug should not be used with cobicistat and protease inhibitors.

Use: In combination with a ritonavir-boosted HIV protease inhibitor and at least 1 other antiretroviral drug, for the treatment of HIV-1 infection in antiretroviral therapy-experienced patients

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild or moderate liver dysfunction (Child-Pugh A or B): No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Not recommended.


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


Data not available

Comments: This drug is highly protein-bound; significant removal via hemodialysis or peritoneal dialysis is not likely.

Other Comments

Administration advice:
-Administer with food.
-Use in combination with a ritonavir-boosted protease inhibitor and at least 1 other antiretroviral drug.
-Administer antacids at least 2 hours before or after this drug.

Storage requirements:
-Store below 30C (86F) in original bottle

-Treatment history and resistance testing (if available) should guide the use of elvitegravir-containing regimens.
-The manufacturer product information for the coadministered protease inhibitor, ritonavir, and other coadministered antiretroviral drugs should be consulted.